Recent advances in antimicrobial peptide-based therapy

• Published in: Bioorganic chemistry 2024-04, Vol.145, p.107151-107151, Article 107151
• Main Authors: Mulukutla, Aditya, Shreshtha, Romi, Kumar Deb, Vishal, Chatterjee, Pallabi, Jain, Utkarsh, Chauhan, Nidhi
• Format: Article
• Language: English
• Subjects: Antibacterial; Antifungal; Antimicrobial peptides; Antiviral; Immunotherapy
• ISSN: 0045-2068; 1090-2120
• DOI: 10.1016/j.bioorg.2024.107151

[Display omitted] Antimicrobial peptides (AMPs) are a group of polypeptide chains that have the property to target and kill a myriad of microbial organisms including viruses, bacteria, protists, etc. The first discovered AMP was named gramicidin, an extract of aerobic soil bacteria. Further studies discovered that these peptides are present not only in prokaryotes but in eukaryotes as well. They play a vital role in human innate immunity and wound repair. Consequently, they have maintained a high level of intrigue among scientists in the field of immunology, especially so with the rise of antibiotic-resistant pathogens decreasing the reliability of antibiotics in healthcare. While AMPs have promising potential to substitute for common antibiotics, their use as effective replacements is barred by certain limitations. First, they have the potential to be cytotoxic to human cells. Second, they are unstable in the blood due to action by various proteolytic agents and ions that cause their degradation. This review provides an overview of the mechanism of AMPs, their limitations, and developments in recent years that provide techniques to overcome those limitations. We also discuss the advantages and drawbacks of AMPs as a replacement for antibiotics as compared to other alternatives such as synthetically modified bacteriophages, traditional medicine, and probiotics.